Lupin surges as its arm achieves NABL accreditation across all greenfield labs
Lupin is currently trading at Rs. 2134.10, up by 45.25 points or 2.17% from its previous closing of Rs. 2088.85 on the BSE.
The scrip opened at Rs. 2087.90 and has touched a high and low of Rs. 2135.70 and Rs. 2085.00 respectively. So far 9279 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1493.75 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 2139.00 and Rs. 1929.00 respectively. The current market cap of the company is Rs. 97047.47 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 46.88% and 6.20% respectively.
Lupin’s wholly owned subsidiary -- Lupin Diagnostics (LDL) has achieved 100% National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation across all its greenfield labs. This notable achievement highlights the adherence to rigorous quality control measures, reinforcing LDL’s unwavering dedication to providing top-tier diagnostic services. The company’s commitment to quality is reflected in every aspect of its operations, ensuring patients receive accurate and timely results that they can trust.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
